Piper Sandler cuts Cigna stock price target on rebate headwinds
Piper Sandler reduced its price target for Cigna (CI) to $360 from $370, citing rebate pool contraction and declining GLP-1 medication coverage. The firm expects high single-digit earnings declines in 2027. Despite this, Cigna's stock is trading at $301.45, below its Fair Value of $461.38. Cigna reported a Q3 2026 EPS beat and raised its 2026 guidance. Bernstein SocGen raised its target to $390, citing growth outlook.
How this was made
The 30-second read
Why it matters
The downgrade may trigger short‑term selling but leaves room for upside if operational improvements materialize.
Market read
Analyst target cuts are a common catalyst for price movement; traders may adjust positions accordingly.
What to watch
Possible upside from the Signature transition and broader cost‑control initiatives.
Background
The article summarizes Piper Sandler's revised valuation for Cigna amid concerns over its pharmacy‑benefit business.
Ticker impact
Piper Sandler lowered its price target on Cigna to $360 from $370, citing rebate headwinds and margin pressure.
likely downside pressure as the market prices in the lower target
The target reduction reflects expected earnings decline in pharmacy benefits, which may prompt short‑term selling.
Market effects
Potential pressure on health‑care insurers and pharmacy‑benefit managers as rebate trends tighten.
U.S. market may see modest pullback in health‑care stocks.
Limited to U.S. equities; no immediate global ripple.
Counterpoint
If rebate pressures ease faster than expected, the target cut could be overly pessimistic.
Key entities
- CompanyCigna
U.S. health services insurer (ticker CI).
- Research FirmPiper Sandler
Equity research house issuing the price‑target revision.

